

Neutrophil Dynamics in Acute Coronary Syndrome

Patrick Maréchal,¹ Julien Tridetti,¹ Mai-Linh Nguyen,¹ Odile Wéra,¹ Zheshen Jiang,¹ Maxime Gustin,¹ Anne-Françoise Donneau,² Cécile Oury,^{1,*} Patrizio Lancellotti,^{1,3*}

¹Laboratory of Cardiology, GIGA Cardiovascular Sciences, University of Liège, Department of Cardiology, University of Liège Hospital, Liège, Belgium

²Biostatistics Unit, Department of Public Health, University of Liège, Liège, Belgium

³Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Cotignola, and Anthea Hospital, Bari, Italy

*These authors have contributed equally

Word count: 3873

Address for correspondence:

Prof. Patrizio Lancellotti, MD, PhD

Domaine Universitaire du Sart Tilman, Batiment B35

Department of Cardiology, University of Liège Hospital,

University of Liège, GIGA-Cardiovascular Sciences, CHU du Sart Tilman

4000 Liège, Belgium

Tel: (32-4) 366 71 94 / Fax: (32-4) 366 71 95

Email: plancellotti@chuliege.be

ABSTRACT

Aims: Clinical evidence indicates that innate immune cells may contribute to the onset and outcome of acute coronary syndrome (ACS). Our prospective study aimed at analysing neutrophil phenotypes in ACS and their role in predicting 1-year major cardiovascular events.

Methods: Blood neutrophil phenotypes were analysed by flow cytometry. Differential blood cell count and plasma levels of soluble markers were recorded at admission and at 6-month follow-up.

Results: 108 patients categorized in chronic stable coronary artery disease (n=37), unstable angina (UA) (n=19), Non-ST-Elevation Myocardial Infarction (NSTEMI) (n=25), and ST-Elevation Myocardial Infarction (STEMI) (n=27) were included. STEMI and NSTEMI patients displayed higher neutrophil count and neutrophil-to-lymphocyte ratio (NLR) than stable and UA patients ($P<0.0001$), which normalized at 6-month after MI. STEMI patients were characterized by elevated percentages of band cells in low-density neutrophils ($P=0.007$) and in high-density neutrophils ($P=0.019$) compared to the other patients. Multivariable logistic regression analysis revealed that plasma levels of total MPO was associated with STEMI when compared to stable (OR: 1.434; 95% CI: 1.119-1.837; $P<0.0001$), UA (1.47; 1.146-1.886; $P=0.002$), and NSTEMI (1.213; 1.1-1.134; $P=0.0001$) patients, while increased neutrophil SSC signal intensity was associated with NSTEMI compared to stable patients (3.828; 1.033-14.184; $P=0.045$). Based on multivariable Cox regression analysis, elevated plasma levels of PCSK9 and low-density neutrophil percentage predicted 1-year outcome independently of cardiovascular risk factors (c-index: 0.915; IQR: 0.908-0.929).

Conclusions: Changes in neutrophil phenotype are concomitant to ACS. These changes may differ between STEMI and NSTEMI. They may also contribute to ACS risk and patient outcome.

Keywords: Acute coronary syndrome; inflammation; neutrophil; outcome

INTRODUCTION

Increasing clinical evidence supports the existence of a link between low-grade systemic inflammation and cardiovascular (CV) risk ¹. Plasma level of high-sensitive C-reactive protein (hs-CRP) at the time of acute coronary syndrome (ACS) and its rise after the incident disease have been associated with a higher risk of major CV event ². CRP is produced by the liver in response to elevation of pro-inflammatory cytokines such as IL-6 and IL-1 β , two well-recognized players in atherosclerosis progression. In the CANTOS trial ³, dampening inflammation by targeting the IL-1 β pathway at the time of ACS lowered the risk of recurrent major CV events in patients who experienced a previous ACS. Hence, inflammation is currently considered as a modifiable CV risk factor. Among other inflammation-related risk factors, several studies pointed to the differential white blood cell count, with a particular focus on neutrophils, lymphocytes and monocytes. Neutrophil count by itself could predict both acute and chronic CVD ^{4,5}. Interestingly, an elevated neutrophil-to-lymphocyte ratio (NLR) has not only been associated with CVD but also with short-term adverse CVD outcomes, including mortality, coronary artery disease (CAD), stroke and heart failure ⁶. Changes in NLR are subsequent to a modification of the balance between innate (neutrophils) and adaptive (lymphocytes) immunity. Also, the association between elevated NLR and poor prognosis in cancer has been linked to cancer-elicited release of immune suppressive neutrophils from the bone marrow ⁷⁻⁹. In view of recent reports on the existence of common risk factors in CVD and cancer ¹⁰, it is therefore possible that CVD might similarly be associated with a mobilisation of neutrophils with altered phenotype, which might contribute to ACS risk. In chronic inflammatory diseases, as in cancer, peripheral blood neutrophils display diversity in their phenotype ⁸. To date, neutrophil phenotypes in coronary artery disease patients and their association with ACS risk and outcome remain unexplored. Our study aimed at providing a first description of neutrophil dynamics in prospectively recruited

coronary artery disease patients. We investigated the association of neutrophil markers with ACS, their evolution after 6 months, as well as their capability to predict patient outcome during 1-year follow-up.

MATERIALS AND METHODS

Patients and study design

A total of 124 patients admitted to our cardiac catheterization lab at University of Liège Hospital were prospectively recruited between March 2017 and October 2018. Patients were classified as chronic stable coronary artery disease (angina symptoms/brief discomfort during exertion or physiological stress and with significant coronary lesions), unstable angina (UA, recent onset or worsening angina for up to 2 months, or resting angina, with or without electrocardiographic changes and significant coronary lesions), Non-ST-Elevation Myocardial Infarction (NSTEMI, troponin elevation above the 99-percentile associated with symptoms compatible with myocardial ischemia without significant elevation of the ST segment), and ST-Elevation Myocardial Infarction (STEMI, troponin elevation above the 99-percentile associated with symptoms consistent with myocardial ischemia with significant ST segment elevation). Patients who displayed angiographically healthy coronary arteries, MI with nonobstructive coronary arteries (MINOCA), Takotsubo syndrome, spontaneous coronary artery dissection, myocarditis and pericarditis or those who did not sign the informed consent were excluded (16 patients out of 124). Patient demographic and clinical characteristics were recorded at admission. Biological variables were measured at admission and after > 6 months for a subset of patients (47%). Composite endpoint at 1-year follow-up was cardiovascular death, stroke, myocardial infarction, or major bleeding. Data at 1-year follow-up was available for 101 patients out of 108. The study was conducted according to the Declaration of Helsinki principles upon approval by the ethical committee of the University of Liège Hospital (2009/205).

Blood samples, sera and platelet poor plasma (PPP) preparation, laboratory measurements

Blood samples from patients were collected from radial or femoral site of arterial catheter and processed within 1 hour. Hematological parameters were determined in EDTA-anticoagulated blood on a Cell-Dyn 3700 (Abbott Laboratories). Platelet poor plasma was obtained after two consecutive centrifugations at 1750g during 15 min at room temperature. Sera were obtained following one centrifugation at 1750g during 15 min at RT. Plasma and sera were stored at -80°C until analysis. IL-6 and S100A9 were measured on EDTA-plasma using a Luminex assay kit (R&D Systems) according to the manufacturer's instructions. Nucleosome levels were quantified on EDTA-plasma with the Cell Death Detection ELISA plus kit (Sigma-Aldrich). Myeloperoxidase quantity and activity were analysed on EDTA-plasma by a method adapted from Franck et al.¹¹ using a human MPO Quantikine ELISA kit (R&D Systems). High sensitivity (hs)-CRP, CK-MB (Abbott Laboratories) and hs-TnT (Roche) were measured in sera by routine immunoassays.

Normal and low-density neutrophil phenotyping

Low density neutrophils (LDNs) and normal density neutrophils (HDNs) were separated from EDTA-anticoagulated blood by density gradient centrifugation (Ficoll-Paque, GE Healthcare) under endotoxin-free conditions. The peripheral blood mononuclear cell (PBMC) fraction contains LDNs and the granulocyte fraction contains HDNs. LDNs and HDNs were phenotyped by flow cytometry using a panel of antibodies directed against CD45 (clone HI30, BD Biosciences), CD66b (clone G10F5, BioLegend), CD11b (clone ICRF44, BD Biosciences), CD16 (clone 3G8, BD Biosciences) and CD10 (clone HI10a, BioLegend) as previously described¹². The gating strategy is shown in supplemental Fig. S1. Data were acquired on a FACSVerse cytometer and analyzed with the FACSuite software (BD Biosciences). Data included levels of CD11b, CD16 and CD10 expressed on the surface of

CD66b positive LDNs and HDNs as well as percentages of neutrophils at different maturation stages in these two cell populations, e.g., segmented cells ($CD10^+CD16^+CD11b^{+/\text{high}}$), band cells ($CD10^{-/\text{low}}CD16^{\text{int}}CD11b^+$), metamyelocytes ($CD10^-CD16^{\text{low}}CD11b^+$), myelocytes ($CD10^-CD16^-CD11b^{\text{low}}$), and promyelocytes ($CD10^-CD16^-CD11b^-$). Cytospins of LDNs and HDNs were performed after positive cell selection by magnetic bead cell sorting (MACS Miltenyi Biotech) using an anti-CD66b antibody (clone G10F5, BioLegend) according to the manufacturer's instructions.

Statistics

Qualitative variables are summarized as numbers and percentages. Normality of the distribution of quantitative variables was tested by Shapiro-Wilk test. Quantitative variables with normal distribution were presented as mean \pm SD, while median (interquartile range [p25-p75]) were reported for quantitative variables with skewed distribution. Qualitative characteristics of patient groups were compared by Chi-square or Fisher exact tests. ANOVA or Kruskal-Wallis tests were applied for quantitative variables as appropriate, with Tukey or DSCF post-hoc test, respectively. Spearman correlation analyses were performed to assess the association between LDN percentage and other quantitative variables. Multinomial logistic regression (MLR) was applied to model association between CAD categories and demographic, clinical and biological variables. Significant variables with $P < 0.1$ after univariate MLR analyses were considered into multivariable MLR analysis ¹³. Results of the final MLR model were presented using odds ratios and corresponding 95% confidence interval. Cox proportional hazard models were used to investigate the occurrence of composite endpoint at 1-year follow-up (cardiovascular death, stroke, myocardial infarction or major bleeding) and to evaluate the prognostic value of changes in neutrophil markers from baseline to 6-month follow-up. Multivariable Cox model for composite endpoint at 1-year follow-up used the same variable selection method as for MLR. All hazard ratios (HR) were

calculated with appropriate unit and corresponding 95% confidence interval. Concordance index (c-index) of the final model was calculated following Uno's method and is presented as c-index with interquartile range (IQR). All tests were performed 2-sided and $P < 0.05$ was considered significant except specified. Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary NC).

RESULTS

Patient characteristics, inflammatory and conventional neutrophil markers

A total of 108 patients were included, 37 (34%) patients had chronic stable coronary artery disease (stable), 19 (18%) UA, 25 (23%) NSTEMI, and 27 (25%) STEMI. Patient demographic and clinical characteristics according to diagnosis are depicted in Table 1. Patients from the four categories did not differ in terms of age, sex and conventional CVD risk factors. However, differences were observed in regard with aspirin ($P=0.0005$) and lipid-lowering therapy ($P=0.001$). Triglyceride levels were more elevated in STEMI patients than in UA ($P=0.009$) and NSTEMI ($P=0.006$). Regarding systemic inflammatory markers, the four patient groups displayed different levels of IL-6 ($P=0.003$) (Table 1). As expected, differences of differential white blood cell counts were observed, mostly related to changes in neutrophil count. NSTEMI and STEMI patients had higher neutrophil counts than stable and UA patients ($P<0.0001$; NSTEMI vs. UA $P=0.012$). Among ACS, NSTEMI patients showed higher monocyte count than stable patients ($P<0.0001$). In contrast, lymphocyte counts did not differ between patient categories. Yet, changes in NLR likely reflected the increase of neutrophil count. Plasma levels of S100A9, total and active MPO, and of nucleosomes, well-known circulating markers of neutrophil activation and NET (neutrophil extracellular trap) release that have previously been associated with CVD risk and ACS¹⁴⁻¹⁷, were higher in STEMI patients than in stable (S100A9: $P=0.013$; total MPO: $P<0.0001$; active MPO: $P<0.0001$; nucleosomes: $P=0.032$) and UA (S100A9: $P=0.018$; total MPO: $P<0.0001$; active

MPO: $P<0.0001$; nucleosomes: $P=0.007$) patients (Fig. 1A). Despite similar increase of neutrophil count in NSTEMI and STEMI patients, the levels of these neutrophil markers were not significantly more elevated in NSTEMI patients than in stable and UA, suggesting that neutrophil phenotype, in addition to absolute cell numbers, differed between STEMI and other ACS conditions. Accordingly, total and active MPO levels were more elevated in STEMI than in NSTEMI patients ($P<0.0001$) (Fig. 1A).

Neutrophil phenotypes in ACS

A detailed phenotypic analysis of neutrophils was performed for the four patient groups. We detected low percentages of LDNs in the PBMC fraction isolated from patient blood, which were not different between patient groups (stable: 0.86 [0.36-1.8]; UA: 0.88 [0.39-1.77]; NSTEMI: 0.95 [0.38-2.1]; STEMI: 1.53 [0.57-6.69], $P=0.272$). LDNs represented a heterogeneous cell population comprising variable proportions of myelocytes, band cells and segmented cells. LDNs displayed features of immature cells, e.g., they were larger and expressed lower levels of CD11b, CD10 and CD16 than HDNs (Fig. S2). The LDN percentage showed a modest correlation with the NLR ($r=0.32$, $P=0.01$), while it was not influenced by any other patients' characteristics. Interestingly, STEMI patients were characterized by elevated percentages of band cells ($CD10^{-/low}CD16^{int}CD11b^+$) in LDNs compared to the three other patient groups ($P=0.007$) (Fig. 1C, Fig. 2A, and Table 1). Few band cells were detected in HDN fraction, with again higher percentages in the blood from STEMI patients than in stable ($P=0.047$) and UA ($P=0.006$) patients (Fig. 2B-D and Table 1). HDNs from NSTEMI patients displayed higher complexity than those from stable ($P=0.003$) and UA ($P=0.031$) patients, as determined by SSC (side scatter) signal intensity (Table 1) (Fig. 1B). There were no significant differences in CD11b, CD16 or CD10 expression levels on the surface of HDNs or LDNs from the four patient groups. Altogether, these data indicate that the increase of neutrophil count in ACS likely reflects elevated numbers of circulating

neutrophils of high density. Distinct phenotypic neutrophil features were identified in STEMI and NSTEMI ACS. Elevated numbers of band cells were detected in the blood from STEMI patients, while NSTEMI patients were characterized by the presence of high-complexity HDNs.

Neutrophil markers in ACS

The association of these neutrophil markers with the four patient groups was assessed. After adjustment with confounding variables, i.e., age, gender, daily low-dose aspirin, and lipid-lowering therapy, plasma levels of total MPO ($P<0.0001$), HDN SSC ($P=0.026$) and hs-cTnT ($P=0.015$) were independently associated with the four patient groups (Table 2). Plasma levels of total MPO were associated with STEMI compared to stable (OR per 1-nM/L increase, 1.434; 95% CI, 1.119-1.837; $P<0.0001$), UA (OR per 1-nM/L increase, 1.47; 95% CI, 1.146-1.886; $P=0.002$), and NSTEMI (OR per 1-nM/L increase, 1.213; 95% CI, 1.1-1.1338; $P=0.0001$) patients. Increased SSC intensity was associated with NSTEMI compared to stable (OR per 10000-MFI increase, 3.828; 95% CI, 1.033-14.184; $P=0.045$).

Total MPO levels correlated with neutrophil count ($r=0.43$, $P=0.0003$) and levels of nucleosomes ($r=0.53$, $P<0.0001$). A moderate correlation was observed with S100A9 levels ($r=0.38$, $P=0.0003$), NLR ($r=0.30$, $P=0.006$), hs-TnT ($r=0.34$, $P=0.002$) and CK-MB ($r=0.24$, $P=0.022$). MPO levels were not influenced by any other patient characteristics or medication. HDN SSC showed a strong positive significant correlation with HDN FSC ($r=0.72$, $P<0.0001$) only.

Prognostic value of neutrophil markers

During 1-year follow-up, 12 patients (4 stable, 2 NSTEMI, 6 STEMI) out of 101 experienced an event. Among stable patients, we recorded 1 stroke, 2 cardiovascular deaths (cardiac arrest, recurrent MI) and 1 bleeding event (BARC 2). In the STEMI group, cardiovascular death (BARC 3b bleeding) occurred in 1 patient, 2 patients had recurrent MI, and 3 patients

experienced major bleeding (2 BARC 2 and 1 BARC 3a). A total of 2 NSTEMI patients had a recurrent MI, which led to death for one of them. We then sought to determine whether neutrophil markers measured at admission could help predicting these major events. Based on univariable Cox regression analysis, elevated neutrophil count, plasma levels of S100A9, PCSK9 and LDN percentage in PBMC predicted 1-year outcome after adjustment for CV risk factors (Table 3). Multivariable analysis indicated that elevated levels of PCSK9 and LDN percentage were independent predictors of outcome (c-index: 0.918; IQR: 0.908, 0.929) (Table 3). Of note, we did not detect any differences of PCSK9 levels between stable, UA, NSTEMI and STEMI patients.

Evolution of neutrophil markers during follow-up

To assess time-dependent changes in neutrophil markers and to determine whether changes concomitant to myocardial injury were maintained at distance of ACS, some of these markers were measured after 6 months post-admission. Data could be obtained for 51 patients from the four categories (18 stable, 11 UA, 11 STEMI, 11 NSTEMI). Baseline characteristics of patients from this subgroup are shown in supplementary Table S2. Although neutrophil count ($P<0.0001$), NLR ($P=0.0004$) and MPO levels ($P=0.0009$) and activity ($P=0.0002$) differed between ACS and stable or UA patients at admission, these markers no longer differed between these patient groups at follow-up (Table S2). Likewise, stable patients who had a previous myocardial infarction (11 patients out of 37) did not differ in any neutrophil markers, i.e., NLR, MPO levels, LDN and band cell percentages, HDN SSC (Table S3). These data indicate that mobilization of neutrophils harbouring a specific phenotype likely occurs at the time of myocardial infarction, which globally resolves over time. We then evaluated the prognostic value of changes in neutrophil markers from baseline to 6-month follow-up. Five out of the 51 patients experienced an event within 1 year (1 stroke, 2 recurrent myocardial infarctions, 2 major bleeding). These analyses revealed a lower probability of

event with larger decrease of neutrophil count (HR: 0.47; CI 95%: 0.24-0.92; $P=0.028$) and NLR (0.45; 0.2-0.97; $P=0.041$) over the follow-up period.

DISCUSSION

Despite advances in understanding the atherosclerotic processes, progression of CAD to acute events remains poorly understood and hardly possible to predict. Several studies indicate that neutrophils are involved in plaque progression ¹⁸⁻²¹, and preclinical data in mice suggest that low-grade systemic inflammation could promote atherosclerosis progression through neutrophil reprogramming ²². Our study provides first clinical evidence that phenotypic modifications of circulating neutrophils occur around the time of ACS. Moreover, we found that these neutrophil phenotypes normalize with time. In addition, differences were found between STEMI and NSTEMI patients. Importantly, we also identified neutrophil markers and neutrophil subpopulations (LDN) that may contribute to CAD outcome independently of known CV risk factors (Fig. S3).

Neutrophil phenotypes in ACS

A series of retrospective and prospective studies concur with a strong capability of NLR to predict CVD patient outcome. Since NLR also predicts outcome in cancer patients, it has been hypothesized that the NLR, as in cancer, could reflect the release of immune suppressor cells (e.g., granulocytic myeloid suppressor cells, G-MDSC) from the bone marrow. So, the NLR would not only be a marker of inflammation but could also reflect a biological process underlying ACS onset. In cancer and in various chronic diseases, G-MDSC can be isolated from the LDN neutrophil subset ^{23,24}. We identified variable percentages of LDN in the PBMC fraction of CAD patients' blood, irrespective of disease stage. Also, we showed that neutrophils with altered phenotype circulate in the blood of STEMI and NSTEMI patients. We identified immature band cells in HDN and LDN from STEMI patient blood, while HDN with high complexity were observed in the blood from NSTEMI patients. Increased

neutrophil complexity depicts higher granularity and changes in internal structures, which generally features early innate immune responses. Circulating neutrophils from NSTEMI patients may therefore have distinct functionality and granular content. Band cells are neutrophils at intermediary stage of maturation, characterized by a curved nucleus. The appearance of these immature cells in the blood results from signals to the bone marrow for increased neutrophil production, as in the case of infection or inflammation. In STEMI, this probably indicates a severe inflammatory response with a high demand for neutrophils, but not only. Importantly, in our whole cohort, increased LDN percentage contributed to predict major CV event at 1-year follow-up after comprehensive multivariable adjustment. Our observation that the LDN percentage moderately correlates with NLR could suggest an important biological role of these cells in CVD outcome that might be independent of inflammation and conventional CV risk factors. In chronic inflammatory diseases such as lupus erythematosus or psoriasis, low-density granulocytes that are more prone to produce NETs are thought to contribute to higher CVD risk^{25,26}. For instance, the frequency of these cells has been associated with non-calcified coronary plaque burden in patients with psoriasis²⁷. Whether LDNs from CAD patients possess immune suppressive or pro-inflammatory function or whether they are more susceptible to release NETs remains to be determined. Nevertheless, the fact that we did not observe any correlation between LDN percentage and the levels of circulating nucleosomes or inflammatory markers while it was moderately correlated with NLR might be in favour of an immune suppressive function.

Soluble neutrophil markers in ACS

We found elevated levels of soluble neutrophil activation markers, including MPO, S100A9 and nucleosomes in STEMI but not in NSTEMI patients and this, despite similar rise in neutrophil count and NLR. Total MPO levels appeared as a strong independent marker of STEMI. These distinct features between NSTEMI and STEMI might reflect different

pathophysiological mechanisms leading to these ACS entities, which could not be picked up based on neutrophil count or NLR only. Noteworthy, it has recently been recognized that beside differences in ECG and troponin levels, plaque composition as well as mechanisms of atherogenesis influence CAD patient outcome ²⁸⁻³⁰. MPO, stored in neutrophil azurophilic granules, is released upon neutrophil activation. Increased circulating levels of this protein have already been shown to predict the outcome of patients with ACS ^{15,16}. MPO would also be a marker of plaque vulnerability ¹⁶. Interestingly, it has been reported that higher circulating MPO levels were found in ACS patients with culprit plaque erosion than in those with culprit plaque rupture ³¹. In addition, luminal thrombi overlying eroded plaques contained higher density of MPO-positive cells, likely neutrophils, than thrombi formed on ruptured plaques. Although there is no clear relationship with culprit lesion morphology and STEMI or NSTEMI entities, our study indicates that MPO levels may reflect different acute complications in CAD, thereby revealing the existence of distinct mechanisms of ACS. It is noteworthy that in agreement with the study by Ferrante et al. ³¹, we did not find any correlation between MPO levels and markers of systemic inflammation, CRP or IL-6, while correlations were observed with other neutrophil-derived markers, like S100A9 and nucleosomes. Hence, neutrophil markers are likely to carry additional information compared to classical inflammatory markers since they may underlie biological mechanisms leading to ACS.

Neutrophil dynamics after ACS

In the study by Kim et al. ⁶, the shorter median time from ACS improved the strength of the association of NLR with a subsequent adverse event. Therefore, it has been suggested that the NLR would increase over time in CVD patients and reach a maximum around the time of event. In our study, in a subset of patients from each category, we could evaluate differential blood cell count, soluble neutrophil markers and inflammation at 6-months post-MI. We

showed that neutrophil count, NLR and soluble neutrophil markers returned to levels of stable patients during the follow-up period, therefore confirming that these markers reach a maximum around the time of ACS. Notably, we found that the levels of changes between the baseline measurements of neutrophil count and NLR and the 6-month follow-up measurements might predict the occurrence of CV events.

Clinical implications

Our study highlights potential roles for neutrophil phenotypes as novel diagnostic and prognostic biomarkers in CAD. Advances in the cellular biology of atherosclerosis and its pathogenesis have led to major advances in its treatment. We provide first evidence that neutrophils could be a key player in the disease progression to ACS through changes in their phenotype and secretory profiles. Targeting pro-inflammatory or immune regulatory neutrophils (specific neutrophil subsets) and/or their downstream mediators that promote adverse effects (e.g., NET, pro-inflammatory cytokines, reactive nitrogen/oxygen species, neutrophil serine proteases, danger-associated molecular pattern molecules) may thus represent new therapeutic opportunities. Deoxyribonuclease (DNase), an enzyme that breaks down NET, has been shown in a clinical study of STEMI patients to accelerate lysis of coronary thrombi ³². Colchicine, an anti-inflammatory agent, has been shown to acutely suppress caspase-1 activity and inhibit inflammasome related cytokines in monocytes from ACS patients ³³. The use of colchicine in patients with recent myocardial infarction was also effective in reducing CV events ³⁴. In patients with a history of myocardial infarction and elevated hs-CRP, canakinumab, targeting IL-1 β , represented another drug effective at preventing adverse cardiac events ³. Serine proteases liberated from activated neutrophils, e.g., cathepsin G, elastase, proteinase-3, are potent regulators of at least six IL-1 cytokine family members, including IL-1 β ³⁵. One might consider inhibiting these extracellular proteases since this strategy will not affect neutrophil antimicrobial capability ³⁵. Neutrophils

may indeed represent a major source of IL-1 β in ACS. In cancer, IL-1 β and S100A9 have been involved in the mobilization of pro-tumoral immature neutrophils with immune suppressive functions^{36,37}. These molecules might also contribute to the production of immune suppressive neutrophils at the time of ACS. Hence, our study may pave the way toward new therapeutic avenues in ACS, which could be based on available immunotherapy approaches.

Limitations

The number of patients examined may be perceived as low. Nevertheless, our study of neutrophil profiles is unique, as it required good logistics coordination, involving both the laboratory and the clinics. Neutrophils need to be processed in a highly standardized manner within 1-hour after blood collection. Blood samples were only obtained during working days. The neutrophil profile during follow-up was obtained in only half of the patients. Given the distinct function of each neutrophil subpopulation, it is likely that each subset participates in the inflammatory pathophysiology of CAD to varying degrees. The relationship between the neutrophil phenotypes and the types of cytokines, reactive oxygen/nitrogen species, serine proteases released has not been studied. In addition, our study does not bring out a causal link between the neutrophilic profile and the destabilization of the coronary disease. It must be considered hypothesis-generating, even if the secretory and morphological dynamics of neutrophils are suggestive. Future larger studies evaluating the prognostic role of neutrophils in ACS are needed.

Conclusion

Our study indicates that in patients with CAD changes in neutrophil phenotypes occur concomitantly to ACS. These changes may reflect different acute complications of CAD and reveal new biological processes leading to ACS. Importantly, the presence of LDN in the blood of CAD patients may represent a novel CVD risk factor.

Funding/Support

C.O. is Research Director at the National Fund for Scientific Research, Belgium (F.R.S.-FNRS).

Disclosures

The authors have nothing to disclose.

REFERENCES

1. Koenig W. Low-Grade Inflammation Modifies Cardiovascular Risk Even at Very Low LDL-C Levels: Are We Aiming for a Dual Target Concept? *Circulation* 2018; **138**:150-153.
2. Mani P, Puri R, Schwartz GG, et al. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. *JAMA Cardiol* 2019; **4**:314-320.
3. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* 2017; **377**:1119-1131.
4. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. *Expert Rev Cardiovasc Ther* 2013; **11**:55-59.
5. Guasti L, Dentali F, Castiglioni L, et al. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects. *Thromb Haemost* 2011; **106**:591-599.
6. Kim S, Eliot M, Koestler DC, Wu WC, Kelsey KT. Association of Neutrophil-to-Lymphocyte Ratio With Mortality and Cardiovascular Disease in the Jackson Heart Study and Modification by the Duffy Antigen Variant. *JAMA Cardiol* 2018; **3**:455-462.
7. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst* 2014; **106**:dju124.
8. Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P. Neutrophil Diversity in Health and Disease. *Trends Immunol* 2019; **40**:565-583.
9. Mackey JBG, Coffelt SB, Carlin LM. Neutrophil Maturity in Cancer. *Front Immunol* 2019; **10**:1912.
10. Lancellotti P, Marechal P, Donis N, Oury C. Inflammation, cardiovascular disease, and cancer: a common link with far-reaching implications. *Eur Heart J* 2019.

11. Franck T, Kohnen S, Boudjeltia KZ, et al. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. *Talanta* 2009; **80**:723-729.
12. Marini O, Costa S, Bevilacqua D, et al. Mature CD10(+) and immature CD10(-) neutrophils present in G-CSF-treated donors display opposite effects on T cells. *Blood* 2017; **129**:1343-1356.
13. Vergouwe Y, Royston P, Moons KG, Altman DG. Development and validation of a prediction model with missing predictor data: a practical approach. *J Clin Epidemiol* 2010; **63**:205-214.
14. Marinkovic G, Grauen Larsen H, Yndigegn T, et al. Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after myocardial infarction. *Eur Heart J* 2019; **40**:2713-2723.
15. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. *Circulation* 2003; **108**:1440-1445.
16. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. *N Engl J Med* 2003; **349**:1595-1604.
17. Borissoff JI, Joosen IA, Versteylen MO, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. *Arterioscler Thromb Vasc Biol* 2013; **33**:2032-2040.
18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; **352**:1685-1695.
19. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. *Circ Res* 2012; **110**:875-888.
20. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. *Circulation* 2002; **106**:2894-2900.

21. Pertiwi KR, van der Wal AC, Pabittei DR, et al. Neutrophil Extracellular Traps Participate in All Different Types of Thrombotic and Haemorrhagic Complications of Coronary Atherosclerosis. *Thromb Haemost* 2018; **118**:1078-1087.

22. Geng S, Zhang Y, Lee C, Li L. Novel reprogramming of neutrophils modulates inflammation resolution during atherosclerosis. *Sci Adv* 2019; **5**:eaav2309.

23. Silvestre-Roig C, Hidalgo A, Soehnlein O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. *Blood* 2016; **127**:2173-2181.

24. Scapini P, Marini O, Tecchio C, Cassatella MA. Human neutrophils in the saga of cellular heterogeneity: insights and open questions. *Immunol Rev* 2016; **273**:48-60.

25. Hacbarth E, Kajdacsy-Balla A. Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumatic fever. *Arthritis Rheum* 1986; **29**:1334-1342.

26. Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. *Semin Immunopathol* 2013; **35**:455-463.

27. Teague HL, Varghese NJ, Tsoi LC, et al. Neutrophil Subsets, Platelets, and Vascular Disease in Psoriasis. *JACC Basic Transl Sci* 2019; **4**:1-14.

28. Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment. *Circulation* 2017; **136**:1155-1166.

29. Libby P. Superficial erosion and the precision management of acute coronary syndromes: not one-size-fits-all. *Eur Heart J* 2017; **38**:801-803.

30. Brezinski ME. Comparing the Risk Factors of Plaque Rupture and Failed Plaque Healing in Acute Coronary Syndrome. *JAMA Cardiol* 2019; **4**:329-331.

31. Ferrante G, Nakano M, Prati F, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. *Circulation* 2010; **122**:2505-2513.

32. Mangold A, Alias S, Scherz T, et al. Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size. *Circ Res* 2015; **116**:1182-1192.

33. Martinez GJ, Robertson S, Barraclough J, et al. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. *J Am Heart Assoc* 2015; **4**:e002128.

34. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med* 2019.

35. Clancy DM, Sullivan GP, Moran HBT, et al. Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing. *Cell Rep* 2018; **22**:2937-2950.

36. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. *Cancer Cell* 2008; **14**:408-419.

37. Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. *J Clin Invest* 2013; **123**:4595-4611.

Table 1. Patient characteristics and neutrophil markers according to CAD category

	Stable n=37	UA n=19	NSTEMI n=25	STEMI n=27	P
Age (yrs)	69 ± 9	67 ± 11	63 ± 12	64 ± 10	0.081
Male gender, n (%)	25 (67.6)	17 (89.5)	19 (76)	20 (74.1)	0.356
Smoking, n (%)	24 (64.9)	12 (63.2)	15 (60)	22 (81.5)	0.343
Body mass index	27.8 (25.3- 31.0)	28.7 (24.6- 34.3)	26.8 (25.4-29.7)	26.9 (24.2-31.0)	0.616
Hypertension, n (%)	29 (78.4)	16 (84.2)	14 (56)	18 (66.7)	0.133
Hypercholesterolemia, n (%)	25 (67.6)	13 (68.4)	13 (52)	13 (48.1)	0.302
Diabetes, n (%)	13 (35.1)	8 (42.1)	5 (20)	8 (29.6)	0.425
Chronic renal failure, n (%)	5 (13.5)	3 (15.8)	1 (4)	4 (14.8)	0.530
Chronic inflammatory disease, n (%)	7 (18.9)	2 (10.5)	0 (0)	4 (14.8)	0.107
Active cancer, n (%)	0 (0)	2 (10.5)	2 (8)	4 (14.8)	0.069
History of DVT, n (%)	2 (5.4)	1 (5.3)	0 (0)	2 (7.4)	0.669
History of stroke, n (%)	4 (10.8)	2 (10.5)	0 (0)	0 (0)	0.086
History of MI, n (%)	11 (29.7)	4 (21.1)	1 (4)	7 (25.9)	0.095
History of CABG, n (%)	6 (16.2)	2 (10.5)	3 (12)	1 (3.7)	0.475
History of PCI, n (%)	12 (32.4)	10 (52.6)	5 (20)	8 (29.6)	0.145
Aspirin, n (%)	31 (83.8)	15 (78.9)	9 (36)	15 (55.6)	0.0005
DAPT, n (%)	5 (13.5)	1 (5.3)	3 (12)	3 (11.1)	0.886
Anticoagulant, n (%)	1 (2.7)	1 (5.3)	0 (0)	1 (3.7)	0.878
Lipid-lowering drug, n (%)	28 (75.7)	14 (73.7)	8 (32)	12 (44.4)	0.001
hs-cTnT (ng/L)	13 (8-23)	16 (10-20)	689 (303-1304) ^{a,b}	293 (19-1438) ^{a,b}	<0.0001
CK-MB (μg/L)	2.80 (2.00- 4.50)	2.50 (1.80- 3.50)	22.50 (14.80- 60.00) ^{a,b}	4.94 (2.50- 47.56) ^{a,b}	<0.0001
Creatinine (mg/dL)	1.08 (0.90- 1.30)	1.00 (0.88- 1.23)	0.94 (0.81-1.09)	0.95 (0.86-1.13)	0.207
Total cholesterol (mg/dL)	155 (138-181)	142 (126-208)	170 (143-211)	181 (142-195)	0.299
LDL (mg/dL)	87 (68-106)	78 (72-127)	109 (91-137)	111 (73-143)	0.052
HDL (mg/dL)	44 (36-53)	35 (29-45)	39 (34-48)	39 (34-49)	0.162
Triglycerides (mg/dL)	113 (88-180)	139 (100-197)	136 (101-165)	82 (62-114) ^{b,c}	0.003
Apo A-I (g/dL)	1.32 (1.11- 1.48)	1.14 (1.03- 1.40)	1.29 (1.14-1.44)	1.21 (1.08-1.40)	0.497
Apo B (g/dL)	0.77 (0.61- 0.90)	0.79 (0.74- 1.05)	0.95 (0.85-1.08)	0.91 (0.70-1.07)	0.081
Lipoprotein (a) (nmol/L)	15 (8-70)	35 (10-118)	33 (10-135)	25 (9-116)	0.727
PCSK9 (pg/mL)	45514 (29768- 85118)	55279 (23275- 74669)	58512 (27008- 78619)	76762 (33957- 127092)	0.307
Lymphocyte count (1000/μL)	1.41 (1.06- 1.77)	1.82 (0.95- 2.24)	1.79 (1.39-2.20)	1.54 (1.20-2.13)	0.185
Monocyte count (1000/μL)	0.46 (0.33- 0.58)	0.53 (0.39- 0.76)	0.73 (0.59-0.92) ^a	0.64 (0.46-0.86)	<0.0001
Neutrophil count (1000/μL)	3.0 (2.1-4.5)	3.9 (2.5-5.2)	5.8 (4.6-8.3) ^{a,b}	7.4 (6.4-9.7) ^{a,b}	<0.0001
Eosinophil count (1000/μL)	0.12 (0.06- 0.25)	0.12 (0.05- 0.24)	0.06 (0.04-0.13)	0.07 (0.04-0.13)	0.094
Basophil count (1000/μL)	0.05 (0.04- 0.08)	0.06 (0.04- 0.07)	0.06 (0.04-0.08)	0.06 (0.04-0.07)	0.98
Hematocrit (%)	42 (41-47)	44 (41-48)	45 (42-48)	42 (38-47)	0.346
Platelet count (1000/μL)	255 ± 71	243 ± 63	247 ± 81	279 ± 72	0.309
Mean platelet volume (fL)	7.8 (7.4-8.3)	7.8 (7.6-8.8)	7.8 (7.1-8.3)	7.6 (7.0-8.5)	0.455
NLR	2.3 (1.8-3.2)	2.2 (1.7-3.1)	3.7 (2.3-5.3) ^a	4.9 (2.7-7.5) ^{a,b}	<0.0001

PLR	157 (141-244)	138 (112-239)	144 (119-170)	174 (122-209)	0.212
hs-CRP (mg/L)	2.93 (0.84-6.87)	1.26 (0.58-4.51)	6.09 (2.62-19.55)	2.51 (0.68-13.22)	0.082
IL-6 (pg/mL)	1.7 (0.4-3.4)	0.7 (0.2-1.5)	2.8 (0.9-13.0)	3.0 (0.8-12.3)	0.033
S100A9 (pg/mL)	213 (142-399)	250 (126-361)	273 (213-466)	431 (292-621) ^{a,b}	0.008
Active MPO (ng/mL)	1.5 (1.2-3.2)	1.4 (1.1-1.9)	2.0 (1.5-3.2)	8.4 (4.9-13.2) ^{a,b,c}	<0.0001
Total MPO (ng/mL)	4.1 (2.9-7.2)	3.7 (2.6-5.5)	5.7 (4.1-8.1)	23.6 (18.6-27.0) ^{a,b,c}	<0.0001
Nucleosomes (AU)	0.04 (0.02-0.11)	0.03 (0.02-0.06)	0.06 (0.04-0.15)	0.09 (0.05-0.22) ^{a,b}	0.006

Neutrophil phenotypes

HND					
SSC	67704 (61896- 74737)	68632 (63191- 76788)	83690 (72344- 99563) ^{a,b}	72985 (64586- 92739)	0.034
FSC	100264 (90863- 111559)	98243 (92717- 108761)	119603 (104467- 130478)	105721 (90881- 120638)	0.108
CD11b (MFI)	12108 ± 4070	12236 ± 4527	13798 ± 4300	14150 ± 3541	0.215
CD10 (MFI)	12254 ± 3501	12840 ± 3353	12170 ± 3931	11756 ± 4358	0.463
CD16 (MFI)	94082 (83307- 137384)	97458 (74226- 113011)	82009 (65544- 102078)	83194 (65209- 108398)	0.344
Band cells (%)	0.03 (0.01- 0.08)	0.01 (0.00- 0.06)	0.02 (0.01-0.09)	0.11 (0.03- 0.36) ^{a,b}	0.019
LDN					
% in PBMC	0.86 (0.36- 1.80)	0.88 (0.39- 1.77)	0.95 (0.38-2.10)	1.53 (0.57- 6.69)	0.272
Band cells (%)	2.5 (1.2-6.8)	2.7 (1.0-6.5)	2.7 (1.8-7.3)	9.5 (4.0-13.7) ^{a,b,c}	0.007

Abbreviations: Apo A-I, apolipoprotein A-I; Apo B, apolipoprotein B; CABG, coronary artery bypass grafting; CK-MB, creatine kinase-myocardial band; DAPT, dual antiplatelet therapy; DVT, deep venous thrombosis; FSC, forward scatter; HDL, high density lipoprotein; HDN, normal density neutrophil; hs-cTnT, high sensitivity cardiac troponin T; hs-CRP, high-sensitivity C-reactive protein; LDL, low density lipoprotein; LDN, low density neutrophil; MFI, median intensity of fluorescence; MI, myocardial infarction; MPO, myeloperoxidase; NLR, neutrophil-to-lymphocyte ratio; PBMC, peripheral blood mononuclear cells; PCI, percutaneous coronary intervention; PLR, platelet-to-lymphocyte ratio; SSC, side scatter. Continuous data are presented as mean±SD or median (IQR).

^a indicates $P<0.05$ vs. stable; ^b $P<0.05$ vs. UA; ^c $P<0.05$ vs. NSTEMI; ^d $P<0.05$ vs. STEMI.

Table 2. Multivariable multinomial logistic regression model for CAD category*

Variable	Comparison	Unit	Odds Ratio (95% CI)	P
hs-cTnT (ng/L)	NSTEMI vs. Stable	10	1.062 (1.020-1.105)	0.003
	STEMI vs. Stable	10	1.061 (1.019-1.104)	0.004
	Unstable vs. Stable	10	0.953 (0.824-1.103)	0.288
	NSTEMI vs. Unstable	10	1.114 (0.961-1.291)	0.152
	STEMI vs. Unstable	10	1.113 (0.960-1.290)	0.156
	NSTEMI vs. STEMI	10	0.999 (0.994-1.004)	0.722
Total MPO (ng/mL)	NSTEMI vs. Stable	1	1.182 (0.919-1.519)	0.193
	STEMI vs. Stable	1	1.434 (1.119-1.837)	<0.0001
	Unstable vs. Stable	1	0.975 (0.857-1.11)	0.703
	NSTEMI vs. Unstable	1	1.212 (0.942-1.559)	0.135
	STEMI vs. Unstable	1	1.47 (1.146-1.886)	0.002
	STEMI vs. NSTEMI	1	1.213 (1.100-1.338)	0.0001
HDN SSC	NSTEMI vs. Stable	10000	3.828 (1.033-14.184)	0.045
	STEMI vs. Stable	10000	3.029 (0.899-10.202)	0.074
	Unstable vs. Stable	10000	1.101 (0.603-2.007)	0.755
	NSTEMI vs. Unstable	10000	3.478 (0.990-12.217)	0.052
	STEMI vs. Unstable	10000	2.752 (0.843-8.977)	0.094
	STEMI vs. NSTEMI	10000	0.791 (0.423-1.478)	0.462

*Adjusted for age, sex, daily low-dose aspirin, lipid-lowering therapy.

Abbreviations: HDN, normal density neutrophil; SSC, side scatter.

Table 3. Predictors of major event at 1-year follow-up*

Variable	Unit	Univariate		Multivariate	
		Hazard Ratio (95% CI)	P	Hazard Ratio (95% CI)	P
Neutrophil count (1000/ μ L)	1	1.18 (1.01-1.39)	0.042		
S100A9 (pg/mL)	100	1.25 (1.02-1.55)	0.038		
LDN (%)	0.1	1.03 (1.01-1.05)	0.014	1.04 (1.0-1.08)	0.03
PCSK9 (pg/mL)	10000	1.37 (1.13-1.68)	0.002	1.54 (1.16-2.04)	0.003

*Cox regression analysis after adjustment for cardiovascular risk factors (hypercholesterolemia, smoking, diabetes, active cancer, chronic inflammatory disease, chronic renal failure, previous thrombotic event).

Figure legends

Figure 1. Neutrophil markers according to CAD category. A. Plasma MPO levels. B. SSC signal intensity of high-density neutrophils (HDN) as determined by flow cytometry on blood granulocytic fraction. C. Percentage of band cells in low-density neutrophils (LDN) isolated from peripheral blood mononuclear fraction. Data are presented using Tukey outlier box plots with box limits representing IQR and median in the middle, whiskers' length are equal to 1.5 times of IQR. *indicates $P<0.05$; *** $P<0.001$ vs. Stable; $^{\#}P<0.05$; $^{\#\#}P<0.001$ vs. UA; $^{\$}P<0.05$; $^{\$\$}P<0.01$ vs. NSTEMI.

Figure 2. Neutrophil phenotype in the blood of NSTEMI and STEMI patients. A. CD66b⁺ low density neutrophils (LDNs) from peripheral blood mononuclear cell (PBMC) fraction of STEMI patient blood. B-C. CD66b⁺ high density neutrophils (HDNs) from the granulocytic (GN) fraction of STEMI and NSTEMI patient blood. Representative flow cytometry plots are shown depicting our phenotyping strategy (see Methods section for details). The red frame corresponds to band cells, represented in red on dot plots. Upper left panels represent cytopsin images of sorted CD66b⁺ cells. Segmented cells (black arrowheads), larger segmented cells (yellow arrowhead), band cells (*) myelocytes (**). Bars represent 10 μ m.

LIST OF SUPPLEMENTAL DIGITAL CONTENT

Supplemental digital content.pdf

Including 3 Figures and 3 Tables

Figure 1



A**STEMI-LDNs**

Figure 1





B**STEMI-HDNs****C****NSTEMI-HDNs**

Figure 2

